Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Insulin Formulations: Types and Delivery

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...

Type II Diabetes I: Introduction

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Carbohydrate Metabolism

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Safety and Effectiveness of MiniMed™ 780G Advanced Hybrid Closed-Loop Use with Ultrarapid Insulin Lispro-AABC in Pediatric and Adult Type 1 Diabetes.

Diabetes technology & therapeutics·2026

Same author

Continuous and Intermittent Glucose Monitoring in 2025.

Diabetes technology & therapeutics·2026

Same author

Psychosocial outcomes among adults with type 1 diabetes using a tubeless automated insulin delivery system compared with sensor augmented pump therapy: A randomised, parallel-group clinical trial sub-study.

Diabetes, obesity & metabolism·2026

Same author

Automated basal insulin delivery versus multiple daily injections in type 1 diabetes: results from a randomized parallel controlled trial.

Frontiers in endocrinology·2026

Same author

Erratum. Use of the Omnipod 5 Automated Insulin Delivery System Activity Feature Reduces Insulin Delivery and Attenuates the Drop in Glycemia Associated With Exercise in a Randomized Controlled Trial. Diabetes Care 2025;48:1598-1606.

Diabetes care·2025

Same author

Safety and Glycemic Outcomes of the MiniMed 780G System with a Disposable All-in-One Sensor.

Diabetes technology & therapeutics·2025

Search research articles

Related Experiment Video

Updated: Jun 12, 2026

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Insulin pump use in type 2 diabetes.

Bruce W Bode¹

¹Atlanta Diabetes Associates, 77 Collier Road, Atlanta, GA 30309, USA. bbode001@aol.com

Diabetes Technology & Therapeutics

|June 3, 2010

Summary

Continuous subcutaneous insulin infusion (CSII) offers potential for type 2 diabetes mellitus (T2DM), but evidence is mixed. CSII may be best for patients whose multiple daily injections (MDI) therapy has not succeeded.

Area of Science:

Endocrinology
Metabolic Diseases
Pharmacological Interventions

Background:

Continuous subcutaneous insulin infusion (CSII) is an emerging treatment for type 2 diabetes mellitus (T2DM).
Clinical evidence regarding CSII efficacy in T2DM remains inconsistent, with varying conclusions from different study sizes.
Investigating simpler CSII regimens is crucial for potentially enhancing patient outcomes.

Purpose of the Study:

To evaluate the current evidence for CSII in T2DM management.
To compare CSII with multiple daily injections (MDI) in T2DM patients.
To identify potential future research directions for CSII in T2DM.

Main Methods:

Review of existing randomized controlled trials (RCTs) comparing CSII and MDI for T2DM.

More Related Videos

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Lepr^db Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

Related Experiment Videos

Last Updated: Jun 12, 2026

Improving IV Insulin Administration in a Community Hospital

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Leprdb Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Lepr^db Mouse Model of Type 2 Diabetes: Pancreatic Islet Isolation and Live-cell 2-Photon Imaging Of Intact Islets

Published on: May 11, 2015

Analysis of smaller trials suggesting CSII superiority versus larger trials indicating equivalence.

Exploration of research into simplified CSII regimens and concentrated insulins (U-500).

Main Results:

Large RCTs found CSII to be equivalent to MDI for T2DM.
Smaller studies indicated CSII superiority over MDI.
Simpler CSII regimens and U-500 insulin are under investigation but not yet clinically implemented.

Conclusions:

CSII may be a viable option for select T2DM patients.
CSII is particularly relevant for individuals who have not achieved success with MDI therapy.
Further research is needed to optimize CSII delivery and insulin formulations for T2DM.